Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-25T04:22:19.658Z Has data issue: false hasContentIssue false
  • English
  • Français

Treating agitated demented patients is difficult and not cheap!

Published online by Cambridge University Press:  01 August 2022

Carl Salzman
Carl Salzman*
Affiliation:
Harvard Medical School, Beth Israel Deaconess/Massachusetts Mental Health Center, Boston, MA, USA
*
Email: [email protected]
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 34 , Special Issue 10: Issue Theme: Pharmacotherapy for Serious Neuropsychiatric Disorders , October 2022 , pp. 865 - 866
Copyright
© International Psychogeriatric Association 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Banerjee, S. et al. (2021). Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet, 398, 1487–1497.CrossRefGoogle ScholarPubMed
Salzman, C. (1994). Clinical Geriatric Psychiatry. Williams & Wilkins.Google Scholar
Khanna, R. et al. (2022). Barriers to treatment of hallucinations and delusions in people with dementia residing in long-term care. Journal of Clinical Psychiatry, 83, 41–47.Google ScholarPubMed
Henderson, C. et al. (2022). Cost-effectiveness of mirtazapine for agitated behaviours in dementia: findings from a randomized controlled trial. International Pyschogeriatrics, 34, 905–917.CrossRefGoogle ScholarPubMed